Zobrazeno 1 - 10 of 890 pro vyhledávání: '"Brachmann SM"'
1
Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Autor: Chapeau EA; Novartis BioMedical Research, Basel, Switzerland. emilie.chapeau@novartis.com., Sansregret L; Novartis BioMedical Research, Basel, Switzerland., Galli GG; Novartis BioMedical Research, Basel, Switzerland., Chène P; Novartis BioMedical Research, Basel, Switzerland., Wartmann M; Novartis BioMedical Research, Basel, Switzerland., Mourikis TP; Novartis BioMedical Research, Basel, Switzerland., Jaaks P; Novartis BioMedical Research, Basel, Switzerland., Baltschukat S; Novartis BioMedical Research, Basel, Switzerland., Barbosa IAM; Novartis BioMedical Research, Basel, Switzerland., Bauer D; Novartis BioMedical Research, Basel, Switzerland., Brachmann SM; Novartis BioMedical Research, Basel, Switzerland., Delaunay C; Novartis BioMedical Research, Basel, Switzerland., Estadieu C; Novartis BioMedical Research, Basel, Switzerland., Faris JE; Novartis BioMedical Research, Cambridge, MA, USA., Furet P; Novartis BioMedical Research, Basel, Switzerland., Harlfinger S; Novartis BioMedical Research, Basel, Switzerland.; AstraZeneca, Oncology R&D, Cambridge, UK., Hueber A; Novartis BioMedical Research, Basel, Switzerland., Jiménez Núñez E; Novartis BioMedical Research, Basel, Switzerland., Kodack DP; Novartis BioMedical Research, Cambridge, MA, USA., Mandon E; Novartis BioMedical Research, Basel, Switzerland., Martin T; Novartis BioMedical Research, Basel, Switzerland., Mesrouze Y; Novartis BioMedical Research, Basel, Switzerland., Romanet V; Novartis BioMedical Research, Basel, Switzerland., Scheufler C; Novartis BioMedical Research, Basel, Switzerland., Sellner H; Novartis BioMedical Research, Basel, Switzerland., Stamm C; Novartis BioMedical Research, Basel, Switzerland., Sterker D; Novartis BioMedical Research, Basel, Switzerland., Tordella L; Novartis BioMedical Research, Basel, Switzerland., Hofmann F; Novartis BioMedical Research, Basel, Switzerland.; Pierre Fabre Group, R&D Medical Care, Toulouse, France., Soldermann N; Novartis BioMedical Research, Basel, Switzerland., Schmelzle T; Novartis BioMedical Research, Basel, Switzerland. tobias.schmelzle@novartis.com.
Publikováno v: Nature cancer [Nat Cancer] 2024 Jul; Vol. 5 (7), pp. 1130.
Zobrazit plný text záznamu
2
Akademický článek
Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Autor: Chapeau EA; Novartis BioMedical Research, Basel, Switzerland. emilie.chapeau@novartis.com., Sansregret L; Novartis BioMedical Research, Basel, Switzerland., Galli GG; Novartis BioMedical Research, Basel, Switzerland., Chène P; Novartis BioMedical Research, Basel, Switzerland., Wartmann M; Novartis BioMedical Research, Basel, Switzerland., Mourikis TP; Novartis BioMedical Research, Basel, Switzerland., Jaaks P; Novartis BioMedical Research, Basel, Switzerland., Baltschukat S; Novartis BioMedical Research, Basel, Switzerland., Barbosa IAM; Novartis BioMedical Research, Basel, Switzerland., Bauer D; Novartis BioMedical Research, Basel, Switzerland., Brachmann SM; Novartis BioMedical Research, Basel, Switzerland., Delaunay C; Novartis BioMedical Research, Basel, Switzerland., Estadieu C; Novartis BioMedical Research, Basel, Switzerland., Faris JE; Novartis BioMedical Research, Cambridge, MA, USA., Furet P; Novartis BioMedical Research, Basel, Switzerland., Harlfinger S; Novartis BioMedical Research, Basel, Switzerland.; AstraZeneca, Oncology R&D, Cambridge, UK., Hueber A; Novartis BioMedical Research, Basel, Switzerland., Jiménez Núñez E; Novartis BioMedical Research, Basel, Switzerland., Kodack DP; Novartis BioMedical Research, Cambridge, MA, USA., Mandon E; Novartis BioMedical Research, Basel, Switzerland., Martin T; Novartis BioMedical Research, Basel, Switzerland., Mesrouze Y; Novartis BioMedical Research, Basel, Switzerland., Romanet V; Novartis BioMedical Research, Basel, Switzerland., Scheufler C; Novartis BioMedical Research, Basel, Switzerland., Sellner H; Novartis BioMedical Research, Basel, Switzerland., Stamm C; Novartis BioMedical Research, Basel, Switzerland., Sterker D; Novartis BioMedical Research, Basel, Switzerland., Tordella L; Novartis BioMedical Research, Basel, Switzerland., Hofmann F; Novartis BioMedical Research, Basel, Switzerland.; Pierre Fabre Group, R&D Medical Care, Toulouse, France., Soldermann N; Novartis BioMedical Research, Basel, Switzerland., Schmelzle T; Novartis BioMedical Research, Basel, Switzerland. tobias.schmelzle@novartis.com.
Publikováno v: Nature cancer [Nat Cancer] 2024 Jul; Vol. 5 (7), pp. 1102-1120. Date of Electronic Publication: 2024 Apr 02.
Zobrazit plný text záznamu
3
Akademický článek
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
Autor: Prahallad A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Weiss A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Voshol H; Novartis Institutes for BioMedical Research, Basel, Switzerland., Kerr G; Novartis Institutes for BioMedical Research, Basel, Switzerland., Sprouffske K; Novartis Institutes for BioMedical Research, Basel, Switzerland., Yuan T; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Ruddy D; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Meistertzheim M; Novartis Institutes for BioMedical Research, Basel, Switzerland., Kazic-Legueux M; Novartis Institutes for BioMedical Research, Basel, Switzerland., Kottarathil T; Novartis Institutes for BioMedical Research, Basel, Switzerland., Piquet M; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Cao Y; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Martinuzzi-Duboc L; Novartis Institutes for BioMedical Research, Basel, Switzerland., Buhles A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Adler F; Novartis Institutes for BioMedical Research, Basel, Switzerland., Mannino S; Novartis Institutes for BioMedical Research, Basel, Switzerland., Tordella L; Novartis Institutes for BioMedical Research, Basel, Switzerland., Sansregret L; Novartis Institutes for BioMedical Research, Basel, Switzerland., Maira SM; Novartis Institutes for BioMedical Research, Basel, Switzerland., Graus Porta D; Novartis Institutes for BioMedical Research, Basel, Switzerland., Fedele C; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Brachmann SM; Novartis Institutes for BioMedical Research, Basel, Switzerland.
Publikováno v: Cancer research [Cancer Res] 2023 Dec 15; Vol. 83 (24), pp. 4130-4141.
Zobrazit plný text záznamu
4
Akademický článek
JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS G12C for the Treatment of Solid Tumors.
Autor: Lorthiois E; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Gerspacher M; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Beyer KS; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Vaupel A; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Leblanc C; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Stringer R; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Weiss A; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Wilcken R; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Guthy DA; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Lingel A; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Bomio-Confaglia C; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Machauer R; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Rigollier P; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Ottl J; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Arz D; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Bernet P; Novartis Pharma AG, BaselCH-4056, Switzerland., Desjonqueres G; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Dussauge S; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Kazic-Legueux M; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Lozac'h MA; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Mura C; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Sorge M; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Todorov M; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Warin N; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Zink F; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Voshol H; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Zecri FJ; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts02139, United States., Sedrani RC; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Ostermann N; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Brachmann SM; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland., Cotesta S; Novartis Institutes for BioMedical Research, BaselCH-4056, Switzerland.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2022 Dec 22; Vol. 65 (24), pp. 16173-16203. Date of Electronic Publication: 2022 Nov 18.
Zobrazit plný text záznamu
5
Akademický článek
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Autor: Weiss A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Lorthiois E; Novartis Institutes for BioMedical Research, Basel, Switzerland., Barys L; Novartis Institutes for BioMedical Research, Basel, Switzerland., Beyer KS; Novartis Institutes for BioMedical Research, Basel, Switzerland., Bomio-Confaglia C; Novartis Institutes for BioMedical Research, Basel, Switzerland., Burks H; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Chen X; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., Cui X; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., de Kanter R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Dharmarajan L; Novartis Institutes for BioMedical Research, Basel, Switzerland., Fedele C; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Gerspacher M; Novartis Institutes for BioMedical Research, Basel, Switzerland., Guthy DA; Novartis Institutes for BioMedical Research, Basel, Switzerland., Head V; Novartis Institutes for BioMedical Research, Basel, Switzerland., Jaeger A; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Núñez EJ; Novartis Institutes for BioMedical Research, Basel, Switzerland., Kearns JD; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Leblanc C; Novartis Institutes for BioMedical Research, Basel, Switzerland., Maira SM; Novartis Institutes for BioMedical Research, Basel, Switzerland., Murphy J; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Oakman H; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Ostermann N; Novartis Institutes for BioMedical Research, Basel, Switzerland., Ottl J; Novartis Institutes for BioMedical Research, Basel, Switzerland., Rigollier P; Novartis Institutes for BioMedical Research, Basel, Switzerland., Roman D; Novartis Institutes for BioMedical Research, Basel, Switzerland., Schnell C; Novartis Institutes for BioMedical Research, Basel, Switzerland., Sedrani R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Shimizu T; National Cancer Center Hospital, Tokyo, Japan., Stringer R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Vaupel A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Voshol H; Novartis Institutes for BioMedical Research, Basel, Switzerland., Wessels P; Novartis Pharma AG, Basel, Switzerland., Widmer T; Novartis Pharma AG, Basel, Switzerland., Wilcken R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Xu K; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., Zecri F; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Farago AF; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Cotesta S; Novartis Institutes for BioMedical Research, Basel, Switzerland., Brachmann SM; Novartis Institutes for BioMedical Research, Basel, Switzerland.
Publikováno v: Cancer discovery [Cancer Discov] 2022 Jun 02; Vol. 12 (6), pp. 1500-1517.
Zobrazit plný text záznamu
6
Akademický článek
Disulfidptosis: a novel cell death modality induced by actin cytoskeleton collapse and a promising target for cancer therapeutics.
Autor: Li, Tianyi1 (AUTHOR), Song, Ying2 (AUTHOR), Wei, Lijuan2 (AUTHOR), Song, Xiangyi2 (AUTHOR), Duan, Ruifeng2 (AUTHOR) duanruifeng@jlu.edu.cn
Publikováno v: Cell Communication & Signaling. 10/14/2024, Vol. 22 Issue 1, p1-22. 22p.
Zobrazit plný text záznamu
7
Akademický článek
Adaptor protein Abelson interactor 1 in homeostasis and disease.
Autor: Petersen, Max1,2,3 (AUTHOR), Dubielecka, Pat1,2,3 (AUTHOR) patrycja_dubielecka-szczerba@brown.edu
Publikováno v: Cell Communication & Signaling. 10/1/2024, Vol. 22 Issue 1, p1-26. 26p.
Zobrazit plný text záznamu
8
Akademický článek
A RAC-GEF network critical for early intestinal tumourigenesis.
Autor: Pickering KA; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., Gilroy K; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., Cassidy JW; CRUK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 ORE, UK., Fey SK; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1QH, UK., Najumudeen AK; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., Zeiger LB; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1QH, UK., Vincent DF; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., Gay DM; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., Johansson J; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., Fordham RP; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., Miller B; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., Clark W; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., Hedley A; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., Unal EB; EMBL/CRG Systems Biology Research Unit, Centre for Genomic Regulation (CRC), Barcelona, Spain.; Universitat Pompeu Fabra (UPF), 08003, Barcelona, Spain.; Institute for Theoretical Biology, Humboldt Universität zu Berlin, Berlin, Germany., Kiel C; EMBL/CRG Systems Biology Research Unit, Centre for Genomic Regulation (CRC), Barcelona, Spain., McGhee E; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., Machesky LM; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1QH, UK., Nixon C; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., Johnsson AE; The Babraham Institute, Babraham Hall, Babraham, Cambridge, CB22 3AT, UK., Bain M; IBAHCM and School of Veterinary Medicine, 464 Bearsden Road, Bearsden, Glasgow, G61 1QH, UK., Strathdee D; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK., van Hoof SR; Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM) and Cancer Center Amsterdam, Academic Medical Center, Amsterdam, The Netherlands.; Oncode Institute, Academic Medical Center, Amsterdam, The Netherlands., Medema JP; Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM) and Cancer Center Amsterdam, Academic Medical Center, Amsterdam, The Netherlands.; Oncode Institute, Academic Medical Center, Amsterdam, The Netherlands., Anderson KI; The Francis Crick Institute, Mill Hill Laboratory, London, NW7 1AA, UK., Brachmann SM; Novartis Institutes for BioMedical Research, Klybeckstrasse, 141, 4002, Basel, Switzerland., Stucke VM; Novartis Institutes for BioMedical Research, Klybeckstrasse, 141, 4002, Basel, Switzerland., Malliri A; CRUK Manchester Institute, 553 Wilmslow Road, Manchester, M20 4BX, UK., Drysdale M; Broad Institute, 415 Main St, Cambridge, MA, 02142, United States., Turner M; The Babraham Institute, Babraham Hall, Babraham, Cambridge, CB22 3AT, UK., Serrano L; EMBL/CRG Systems Biology Research Unit, Centre for Genomic Regulation (CRC), Barcelona, Spain., Myant K; Edinburgh Research Centre, The Institute of Genetics and Molecular Medicine, Crewe Road South, Edinburgh, EH4 2XR, UK. kevin.myant@igmm.ed.ac.uk., Campbell AD; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK. a.campbell@beatson.gla.ac.uk., Sansom OJ; CRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK. o.sansom@beatson.gla.ac.uk.; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1QH, UK. o.sansom@beatson.gla.ac.uk.
Publikováno v: Nature communications [Nat Commun] 2021 Jan 04; Vol. 12 (1), pp. 56. Date of Electronic Publication: 2021 Jan 04.
Zobrazit plný text záznamu
9
Akademický článek
Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models.
Autor: Sprouffske K; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Kerr G; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Li C; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Prahallad A; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Rebmann R; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Waehle V; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Naumann U; Biotherapeutic and Analytical Technologies, Novartis Institutes for BioMedical Research, Basel, Switzerland., Bitter H; Disease Area Oncology, Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Jensen MR; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Hofmann F; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Brachmann SM; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Ferretti S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Kauffmann A; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Publikováno v: Computational and structural biotechnology journal [Comput Struct Biotechnol J] 2020 Jan 31; Vol. 18, pp. 323-331. Date of Electronic Publication: 2020 Jan 31 (Print Publication: 2020).
Zobrazit plný text záznamu
10
Akademický článek
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
Autor: Lu H; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Liu C; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Velazquez R; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Wang H; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Dunkl LM; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland., Kazic-Legueux M; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland., Haberkorn A; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland., Billy E; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland., Manchado E; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland., Brachmann SM; Novartis Institutes for BioMedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland., Moody SE; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Engelman JA; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Hammerman PS; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Caponigro G; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Mohseni M; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts., Hao HX; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts. huaixiang.hao@novartis.com.
Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2019 Jul; Vol. 18 (7), pp. 1323-1334. Date of Electronic Publication: 2019 May 08.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje